[Cited March 7, 2026]
When pharmaceutical companies put patient safety on the back burner, users can suffer from serious potential side effects and harm as a result of negligent FDA warnings
78 AmistenSSalehiARorsmanPJonesPMPersaudSJ
Although no significant change was observed in the bone formation marker P1NP, the semaglutide group showed a significant increase in the bone resorption marker CTX and a reduction in areal BMD at both the lumbar spine and total hip
(Although the approval of the monoclonal antibody teplizumab in 2022, which has recently shown promise as a potential cure for Type 1 diabetes, could cut the rate among all age groups.) As such, while GLP-1s support weight management, they should not be considered a cure-all for overall health or other disease states
Para pacientes que consideran suspender o reducir el tratamiento con agonistas GLP-1, existen varias estrategias que pueden ayudar a mantener los beneficios obtenidos, aunque la evidencia sobre su efectividad es limitada